Particle.news

Download on the App Store

NHS England rolls out world-first liquid biopsy to fast-track cancer treatment

Analysis of tumour DNA fragments in blood samples lets doctors identify targeted therapies within days, cutting treatment wait times by more than two weeks.

Image
Image
Rebeca Proctor, 41, who was diagnosed with stage four lung cancer, had a liquid biopsy test
Image

Overview

  • Liquid biopsies have become the default diagnostic approach for suspected lung cancer and advanced breast cancer patients across England, making the NHS the first health service globally to adopt a blood-test first strategy.
  • Pilot data showed ctDNA testing delivered treatment decisions an average of 16 days earlier than standard tissue biopsies, reducing the need for invasive procedures.
  • An estimated 15,000 lung cancer patients and 5,000 breast cancer patients will benefit each year from faster access to personalized therapies.
  • Independent analysis indicates the new testing could save the NHS up to £11 million annually through fewer biopsies and earlier intervention.
  • NHS leaders are exploring extending the liquid biopsy approach to other cancers, including pancreatic and gallbladder, following the successful lung and breast programmes.